CN1857469A - Arasaponin composition preparation and its preparing process - Google Patents
Arasaponin composition preparation and its preparing process Download PDFInfo
- Publication number
- CN1857469A CN1857469A CN 200610046074 CN200610046074A CN1857469A CN 1857469 A CN1857469 A CN 1857469A CN 200610046074 CN200610046074 CN 200610046074 CN 200610046074 A CN200610046074 A CN 200610046074A CN 1857469 A CN1857469 A CN 1857469A
- Authority
- CN
- China
- Prior art keywords
- total
- radix paeoniae
- content
- flavones
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to compound preparation with arasaponin composition as main component for treating cardiac and cerebral vascular diseases. The arasaponin composition contains total haw arasaponin in 1-99 wt% and haw stem and leaf total phenolic acid, gingko leaf flavonid, sowthistle-leaf ixeris flavonid, total paeoniflorin or seabuckthorn flavonid in 1-99 wt%, and is compounded with pharmaceutically acceptable supplementary material to prepare pharmaceutically acceptable preparations. The medicine of the present invention is used in preventing and treating cardiac and cerebral vascular diseases, senile dementia, and other diseases.
Description
Technical field:
The present invention relates to a kind of compound preparation of the treatment cardiovascular and cerebrovascular disease based on notoginseng total saponin compounds (comprising notoginseng stem and leaf total saponin and Radix Notoginseng total arasaponins).And the application of various preparations in pharmaceutical field that utilizes the inventive method to obtain, the particularly application in the medicine of preparation control cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia and other various diseases of causing by cerebral ischemia thereof etc.Make a distinction between the important and the lesser one in the full side of medicine of the present invention, compatibility is proper, and complementation is short mutually.
Background technology:
Radix Notoginseng, Fructus Crataegi, Semen Ginkgo, Herba Ixeritis Sonchifoliae, Radix Paeoniae Rubra, the Radix Paeoniae Alba, Fructus Hippophae all are China's conventional Chinese medicines, and its medicine as the treatment cardiovascular and cerebrovascular disease has basis of clinical application widely and long clinical application history, and evident in efficacy.Modern pharmacology studies show that Radix Notoginseng has multiple important physical activity such as blood circulation promoting and blood stasis dispelling, reduction myocardial oxygen consumption, raising brain oxygen-supplying amount, the growth of promotion cerebral nerve; Total phenolic acids of Caulis Crataegi and Folium Crataegi improves significantly to the blood ability of penetrating, the oxygen metabolism effect tool of heart, can significantly increase cardiac output and cardiac output, increases venous oxygen content, reduces myocardial oxygen consumption, improves the blood supply oxygen supply of cardiac muscle; Folium Ginkgo total flavones and Herba Ixeritis Sonchifoliae total flavones have effects such as blood vessel dilating, blood flow increasing, blood viscosity lowering, quickening blood flow rate, anti-hypoxia; Peoniflorin have promote learning memory disorder due to learning and memory, the antagonism scopolamine, significantly improve learning memory disorder due to the cerebral ischemia re-pouring, improve effects such as body microcirculating state, blood viscosity lowering, the inductive platelet aggregation of inhibition ADP.Modern clinical research shows that Fructus Hippophae total flavones has curative effect preferably for angina pectoris, coronary heart disease.
How to overcome the shortcoming of taking single medicinal material, reasonable compatibility, short complementary mutually, make it to become effective good recipe of the treatment diseases of cardiovascular and cerebrovascular systems and the disease of suffering from a deficiency of the kidney, making it improving aspect performance the best use ofs such as cardio-cerebrovascular function and control aging of brain, raise immunity, slow down aging is its maximum difficult point.
Summary of the invention:
The objective of the invention is defective and deficiency at above-mentioned prior art existence, provide a kind of and can overcome the shortcoming of taking single medicinal material, reasonable compatibility, short complementary mutually, make it to become effective good recipe of treatment diseases of cardiovascular and cerebrovascular systems, make it improving aspect performance the best use ofs such as cardio-cerebrovascular function and control aging of brain, raise immunity, slow down aging.
Further aim of the present invention provides the notoginseng total saponin compounds (compositions of Radix Notoginseng total arasaponins and total phenolic acids of Caulis Crataegi and Folium Crataegi, the compositions of Radix Notoginseng total arasaponins and Folium Ginkgo total flavones, the compositions of Radix Notoginseng total arasaponins and Herba Ixeritis Sonchifoliae total flavones, the compositions of Radix Notoginseng total arasaponins and Radix Paeoniae Alba total glycosides, the compositions of Radix Notoginseng total arasaponins and Fructus Hippophae total flavones) and the application of preparation in pharmaceutical field, particularly be used to prevent and treat the medicine of the diseases such as other dysfunction that cardiovascular and cerebrovascular disease, senile dementia, cerebral ischemia cause in preparation.
The present invention is implemented by following technical proposals.
The present invention relates to a kind of is the method for the compound preparation of main preparation control cardiovascular and cerebrovascular disease, senile dementia, cerebral ischemia and other various diseases of being caused by cerebral ischemia thereof etc. by notoginseng total saponin compounds (comprising notoginseng stem and leaf total saponin and Radix Notoginseng total arasaponins), it is characterized in that this method comprises following content:
(1) gets Radix Notoginseng total arasaponins respectively according to composition by weight calculating and (comprise notoginseng stem and leaf total saponin, Radix Notoginseng total arasaponins, the content of its total saponins should be 40%～100%) 99～1 parts of 1～99 part and total phenolic acids of Caulis Crataegi and Folium Crataegi (content of total phenolic acid is 20%～100% in the total phenolic acids of Caulis Crataegi and Folium Crataegi), respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(2) get Radix Notoginseng total arasaponins respectively according to composition by weight calculating and (comprise notoginseng stem and leaf total saponin, Radix Notoginseng total arasaponins, the content of its total saponins should be 40%～100%) 99～1 parts of 1～99 part and Folium Ginkgo total flavoness (content of total flavone is 20%～100% in the Folium Ginkgo total flavones), respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(3) get Radix Notoginseng total arasaponins respectively according to composition by weight calculating and (comprise notoginseng stem and leaf total saponin, Radix Notoginseng total arasaponins, the content of its total saponins should be 40%～100%) 99～1 parts of 1～99 part and Herba Ixeritis Sonchifoliae total flavoness (content of total flavone is 20%～100% in the Herba Ixeritis Sonchifoliae total flavones), respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(4) get Radix Notoginseng total arasaponins respectively according to composition by weight calculating and (comprise notoginseng stem and leaf total saponin, Radix Notoginseng total arasaponins, the content of its total saponins should be 40%～100%) 1～99 part and Radix Paeoniae Alba total glycosides (comprise Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides, wherein the content of Radix Paeoniae Alba total glycosides is 20%～100%) 99～1 parts, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(5) get Radix Notoginseng total arasaponins respectively according to composition by weight calculating and (comprise notoginseng stem and leaf total saponin, Radix Notoginseng total arasaponins, the content of its total saponins should be 40%～100%) 99～1 parts of 1～99 part and Fructus Hippophae total flavoness (content of total flavone is 20%～100% in the Fructus Hippophae total flavones), respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
The specific embodiment
The following examples can help those skilled in the art more fully to understand the present invention.But do not limit the present invention in any way.
Embodiment 1 Radix Notoginseng Fructus Crataegi freeze-dried powder
Get Radix Notoginseng total arasaponins 2g respectively, total phenolic acids of Caulis Crataegi and Folium Crataegi 0.4g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 2 Radix Notoginseng Folium Ginkgo lyophilized powder pins
Get Radix Notoginseng total arasaponins 1g respectively, Folium Ginkgo total flavones 1.5g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 3 Radix Notoginseng Ixers sonchifolia freeze-dried powders
Get Radix Notoginseng total arasaponins 2g respectively, Herba Ixeritis Sonchifoliae total flavones 2g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 4 Radix Notoginseng Radix Paeoniae freeze-dried powders
Get Radix Notoginseng total arasaponins 2g respectively, Radix Paeoniae Alba total glycosides 0.8g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 5 Radix Notoginseng Fructus Hippophae freeze-dried powders
Get Radix Notoginseng total arasaponins 2g respectively, Fructus Hippophae total flavones 1.5g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 6 Radix Notoginseng Folium Ginkgo capsule
Get Radix Notoginseng total arasaponins 20g respectively, Folium Ginkgo total flavones 5g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 7 Radix Notoginseng Fructus Crataegi capsules
Get Radix Notoginseng total arasaponins 20g respectively, total phenolic acids of Caulis Crataegi and Folium Crataegi 15g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 8 Radix Notoginseng Herba Ixeritis Sonchifoliae capsules
Get Radix Notoginseng total arasaponins 10g respectively, Herba Ixeritis Sonchifoliae total flavones 20g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 9 Radix Notoginseng Radix Paeoniae capsules
Get Radix Notoginseng total arasaponins 10g respectively, Radix Paeoniae Alba total glycosides 15g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 10 Radix Notoginseng Fructus Hippophae capsules
Get Radix Notoginseng total arasaponins 10g respectively, Fructus Hippophae total flavones 15g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
The extraction of embodiment 11 total phenolic acids of Caulis Crataegi and Folium Crataegi, Folium Ginkgo total flavones, Herba Ixeritis Sonchifoliae total flavones, Fructus Hippophae total flavones
(1) takes by weighing hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Fructus Hippophae 1Kg, water or variable concentrations alcohol (comprising ethanol, methanol etc.) extract 1～3 time, and (the solvent consumption is 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filter, reclaim ethanol to there not being the alcohol flavor.Concentrate with suitable quantity of water dissolving (100～1000ml), with organic solvent degreasing (comprise petroleum ether, chloroform, etc., hyposynchronization also can save), extractions such as ethyl acetate or n-butyl alcohol or n-amyl alcohol, get final product behind the recovery organic solvent the total flavones crude product.
(2) take by weighing hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Fructus Hippophae 1Kg, add 6～10 times of water gagings, regulate pH to 8～9, decocted 0.5～3 hour, filter, extract so repeatedly 1～3 time with lime cream.Merge extractive liquid, is chilled to below 70 ℃, regulates pH to 3～5 with acid (comprising mineral acid and organic acid such as acetic acid, trichloroacetic acid such as hydrochloric acid, sulphuric acid), and is static, filter get final product the total flavones crude product.
(3) take by weighing hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Fructus Hippophae 1Kg, water or different concentration ethanol are extracted 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), (comprise polarity, middle polarity and nonpolar macroporous adsorption resin through the separation of macroporous adsorbent resin chromatography post, the ratio of the consumption of resin and crude drug is 1: 0.2～5), water, different concentration ethanol or methanol-eluted fractions successively, collect different concentration ethanol or methanol-eluted fractions fraction, reclaim get final product behind the solvent the different total flavones elaboration of purity.The total flavones crude product that obtains in above-mentioned (1 and 2) also can be by macroporous adsorbent resin chromatography post refining (method be the same).
(4) take by weighing hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Fructus Hippophae 1Kg, water or different concentration ethanol are extracted 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), separate through the polyamide chromatographic column, water, different concentration ethanol or methanol-eluted fractions are collected different concentration ethanol or methanol-eluted fractions fraction successively, reclaim get final product behind the solvent the different total flavones elaboration of purity.The total flavones crude product that obtains in above-mentioned (1 and 2) also can be by polyamide chromatographic column refining (method be the same).
The extraction of embodiment 12 Radix Notoginseng total arasaponinss, Radix Paeoniae Alba total glycosides
(1) take by weighing Radix Notoginseng or Radix Paeoniae 1Kg, water or variable concentrations alcohol (comprising ethanol, methanol etc.) extract 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.Concentrate with suitable quantity of water dissolving (100～1000ml), with organic solvent degreasing (comprise petroleum ether, chloroform, ethyl acetate etc., hyposynchronization also can save), n-butanol extraction (comprising n-amyl alcohol etc.), reclaim get final product behind the n-butyl alcohol thick total glycosides or total saponins slightly.
(2) take by weighing Radix Notoginseng or Radix Paeoniae 1Kg, water or different concentration ethanol are extracted 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), (comprise polarity, middle polarity and nonpolar macroporous adsorption resin through the separation of macroporous adsorbent resin chromatography post, the ratio of the consumption of resin and crude drug is 1: 0.2～5), water, different concentration ethanol eluting successively, collect the different concentration ethanol eluting fraction, get final product different total glycosides or the total saponins elaboration of purity.The thick total saponins that obtains in above-mentioned (1) also can be by macroporous adsorbent resin chromatography post refining (method be the same).
Claims (10)
1, a kind of notoginseng total saponin compounds, it is characterized in that being grouped into (percentage by weight): Radix Notoginseng total arasaponins 1%～99%, total phenolic acids of Caulis Crataegi and Folium Crataegi 99%～1% or Folium Ginkgo total flavones 99%～1% or Herba Ixeritis Sonchifoliae total flavones and saponin 99%～1% or Radix Paeoniae Alba total glycosides (comprising Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides) 99%～1% or Fructus Hippophae total flavones 99%～1% by following one-tenth.More particularly, be Radix Notoginseng total arasaponins refer to said medicine in the combination of any one or two or more medicines, be equipped with proper pharmaceutical excipients and make the pharmaceutically various preparations of acceptable.
2, according to right 1 described preparation, it is characterized in that: the content of total saponins should be 40%～100% in the Radix Notoginseng total arasaponins in the described composition (comprising notoginseng stem and leaf total saponin).
3, according to right 1 described preparation, it is characterized in that: the content of total phenolic acid is 20%～100% in the total phenolic acids of Caulis Crataegi and Folium Crataegi in the described composition.
4, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～100% in the Folium Ginkgo total flavones in the described composition.
5, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～100% in the Herba Ixeritis Sonchifoliae total flavones in the described composition.
6, according to right 1 described preparation, it is characterized in that: the content of the Radix Paeoniae Alba total glycosides in the Radix Paeoniae Alba total glycosides in the described composition (comprising Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides) is 20%～100%.
7, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～100% in the Fructus Hippophae total flavones in the described composition.
8, according to right 1 described preparation of compositions method, it is characterized in that; It is the characteristics according to various compositionss, and the modern preparation technique that allows on the employing pharmaceutics is realized.
9, all kinds of preparations of making according to right 1 described compositions, it is characterized in that: it comprises injection type, peroral dosage form, percutaneous dosing dosage form, mucosa absorption dosage form.
10, all kinds of preparations of making according to right 1 described compositions is characterized in that: be mainly used in the diseases such as other dysfunction that control cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia cause.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610046074 CN1857469A (en) | 2006-03-17 | 2006-03-17 | Arasaponin composition preparation and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610046074 CN1857469A (en) | 2006-03-17 | 2006-03-17 | Arasaponin composition preparation and its preparing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1857469A true CN1857469A (en) | 2006-11-08 |
Family
ID=37296457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610046074 Pending CN1857469A (en) | 2006-03-17 | 2006-03-17 | Arasaponin composition preparation and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1857469A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101250719B (en) * | 2007-12-05 | 2010-04-07 | 南京大学 | Method for one-step synthesing and assembling cuprum nanometer particle |
| CN117100733A (en) * | 2023-10-25 | 2023-11-24 | 广州白云山和记黄埔中药有限公司 | Salvianolic acid B and/or Notoginseng radix total saponin composition and its application |
-
2006
- 2006-03-17 CN CN 200610046074 patent/CN1857469A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101250719B (en) * | 2007-12-05 | 2010-04-07 | 南京大学 | Method for one-step synthesing and assembling cuprum nanometer particle |
| CN117100733A (en) * | 2023-10-25 | 2023-11-24 | 广州白云山和记黄埔中药有限公司 | Salvianolic acid B and/or Notoginseng radix total saponin composition and its application |
| CN117100733B (en) * | 2023-10-25 | 2024-04-05 | 广州白云山和记黄埔中药有限公司 | Salvianolic acid B and/or Notoginseng radix total saponin composition and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857473A (en) | Gynostemma pentaphylla saponin composition preparation and its preparing process | |
| CN101062165A (en) | Citrus aurantium total flavone extract and the preparing method thereof | |
| CN101119740B (en) | Use of radix sanguisorbae and its extract for preparing medicament to increase RBC and hemoglobin | |
| CN1857388A (en) | Preparation and application of notoginseng stem and leaf total saponin composition | |
| CN1857472A (en) | Ginsenoside composition preparation and its preparing process | |
| CN1857441A (en) | Preparation and application of total salvianolic acid composition | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN1314403C (en) | Composition of paeoniflorin and albiflorin and its preparation method | |
| CN101991567A (en) | Application of three biflavone monomer components extracted from ginkgo leaves in preparing medicament of alpha-glucosidase inhibitor | |
| CN1229324C (en) | Extraction process of tanshin general phenolic acid and its prepn and use | |
| CN1857377A (en) | Preparation and application of total safflower flavone composition | |
| CN1857469A (en) | Arasaponin composition preparation and its preparing process | |
| CN1857442A (en) | Preparation and application of ligustrazine and its salt composition | |
| CN1973853B (en) | Hemostatic and analgetic medicine composition and its preparation process | |
| CN100536868C (en) | Powder injection contg high content tanshin polyphenolic acid salts, and its preparation method | |
| CN1857395A (en) | Compound Chinese medicine composition for treating cardiac and cerebral vascular diseases | |
| CN1771978A (en) | Notoginseng triol-saponin composition and its prepn and use | |
| CN100431566C (en) | Chinese medicine composition and its prepn process and application | |
| CN105640970B (en) | Effective part of ginseng stem and leaf and preparation method and application thereof | |
| CN1686200A (en) | Tulip poplar extract, refined extract and its application in medicine preparation | |
| CN1857439A (en) | Preparation and application of ginkgo leaf flavonid composition | |
| EP2083839A2 (en) | Antiviral astragalus extract | |
| CN100479837C (en) | Weinakang for treating ischemic cerebrovascular disease and senile dementia and preparation method thereof | |
| CN1857387A (en) | Preparation and application of pueraria flavonid composition | |
| CN112569294A (en) | Traditional Chinese medicine composition for treating Alzheimer disease and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |